We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
-15.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.41B
AUM Growth
-$2.89B
(-35%)
Cap. Flow
-$1.47B
Cap. Flow
% of AUM
-27.24%
Top 10 Holdings %
Top 10 Hldgs %
37.29%
Holding
165
New
19
Increased
15
Reduced
46
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOGC
LogicBio Therapeutics, Inc. Common Stock
LOGC
|
+$78.1M |
| 2 |
THOR
Synthorx, Inc. Common Stock
THOR
|
+$77.1M |
| 3 |
CVS Health
CVS
|
+$59.3M |
| 4 |
CELG
Celgene Corp
CELG
|
+$58.5M |
| 5 |
Guardant Health
GH
|
+$56.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$149M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$98.5M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$81.7M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$81M |
| 5 |
Edwards Lifesciences
EW
|
+$79.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.11% |
| 2 | Financials | 0.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TCDA
1
DELISTED
Tricida, Inc. Common Stock
TCDA
| $257M | 4.75% |
10,889,280
| – | – |
|
2
Ascendis Pharma A/S
ASND
$16.8B
| $256M | 4.74% |
4,087,373
-68,518
| -2% | -$4.31M |
|
3
Biogen
BIIB
$32.1B
| $251M | 4.65% |
835,249
-75,051
| -8% | -$24M |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $209M | 3.86% |
3,256,700
+792,850
| +32% | +$58.5M |
|
5
Boston Scientific
BSX
$68.3B
| $205M | 3.78% |
5,790,400
-2,073,595
| -26% | -$75.2M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $199M | 3.69% |
2,047,400
-833,703
| -29% | -$98.5M |
|
7
Merck
MRK
$324B
| $191M | 3.53% |
2,614,760
-1,099,771
| -30% | -$77.6M |
|
|
8
Vertex Pharmaceuticals
VRTX
$125B
| $188M | 3.47% |
1,133,200
-467,300
| -29% | -$81M |
|
|
WMGI
9
DELISTED
Wright Medical Group Inc
WMGI
| $134M | 2.47% |
4,905,899
-1,533,669
| -24% | -$42.4M |
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $128M | 2.37% |
957,000
-193,405
| -17% | -$31.7M |
|
|
CMTA
11
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $123M | 2.27% |
10,425,225
| – | – |
|
12
Viatris
VTRS
$20.9B
| $109M | 2.02% |
3,986,200
-793,400
| -17% | -$25.7M |
|
13
Thermo Fisher Scientific
TMO
$215B
| $97.9M | 1.81% |
437,500
-230,500
| -35% | -$54.1M |
|
|
THOR
14
DELISTED
Synthorx, Inc. Common Stock
THOR
| $92.4M | 1.71% |
+5,316,355
| New | +$77.1M |
|
15
Cigna
CI
$78.9B
| $91.7M | 1.7% |
482,700
-151,200
| -24% | -$31.5M |
|
16
Sarepta Therapeutics
SRPT
$1.61B
| $85.2M | 1.58% |
781,000
-73,400
| -9% | -$9.18M |
|
17
Regeneron Pharmaceuticals
REGN
$73.1B
| $83M | 1.53% |
222,100
-172,300
| -44% | -$63.1M |
|
18
Intuitive Surgical
ISRG
$128B
| $81.7M | 1.51% |
511,500
+234,900
| +85% | +$39.8M |
|
19
Elevance Health
ELV
$83.3B
| $80.2M | 1.48% |
305,400
-168,600
| -36% | -$46.4M |
|
20
Inspire Medical Systems
INSP
$1.49B
| $77.3M | 1.43% |
1,829,449
-614,772
| -25% | -$26.1M |
|
21
Illumina
ILMN
$29.3B
| $73.8M | 1.36% |
252,785
-22,205
| -8% | -$6.88M |
|
|
PRNB
22
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $71.4M | 1.32% |
2,605,713
| – | – |
|
|
23
Edwards Lifesciences
EW
$48.5B
| $71.3M | 1.32% |
1,396,800
-1,575,000
| -53% | -$79.7M |
|
|
IMMU
24
DELISTED
Immunomedics Inc
IMMU
| $70.9M | 1.31% |
4,967,403
+638,830
| +15% | +$12.7M |
|
|
LOGC
25
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| $67.3M | 1.24% |
+6,466,783
| New | +$78.1M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q4 2018 Portfolio in Review
As of Q4 2018, OrbiMed held 165 positions worth $5.41B, down 35% from $8.3B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
OrbiMed withdrew a net $1.47B in Q4 2018, closing 34 positions and reducing 46 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials.
Against the trend, OrbiMed opened a new position in LogicBio Therapeutics, Inc. Common Stock worth $67.3M.
- OrbiMed's largest Q4 2018 buy was LogicBio Therapeutics, Inc. Common Stock: 6,466,783 shares worth $67.3M.
- OrbiMed added most to Celgene Corp in Q4 2018, an estimated $58.5M increase.
- OrbiMed's biggest Q4 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $98.5M.
- OrbiMed fully exited Jazz Pharmaceuticals in Q4 2018, selling an estimated $149M.
- OrbiMed's ten largest holdings make up 37% of its $5.41B portfolio in Q4 2018.
- OrbiMed opened 19 new positions and closed 34 in Q4 2018.
- OrbiMed's portfolio value fell 35% quarter-over-quarter to $5.41B.
Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.